Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.58 |
| ▸ | HTR4 | Q13639 | 14/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176553 | 0.97 | HTR3A (0.59) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17176581 | 0.93 | HTR3A (0.57) | HTR3AHTR4KCNH2 | |
| SCHEMBL7107763 | 0.87 | HTR4 (0.56) | HTR3AHTR4KCNH2 | |
| SCHEMBL3157359 | 0.85 | HTR3A (0.64) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17170659 | 0.85 | HTR3A (0.57) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17170656 | 0.82 | HTR3A (0.59) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL19068179 | 0.82 | HTR3A (0.56) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17170595 | 0.77 | HTR3A (0.57) | HTR3AHTR4KCNH2 | |
| SCHEMBL7326328 | 0.75 | HTR4 (0.64) | HTR3AHTR4CHRM2ADRA2BHRH2 | |
| SCHEMBL24916794 | 0.75 | HTR2A (0.50) | HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-0699194-B1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20030139389-A1 | 5-HT4 receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2003-07-24 | — | — | US | disclosed |
| US-20020019386-A1 | 5-HT4 receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-02-14 | — | — | US | disclosed |
| US-6114329-A | 5-HT4 receptor antagonists useful in the treatment of gastroinstestinal, cardiovascular and CNS disorders | SMITHKLINE BEECHAM PLC (GB) | 2000-09-05 | — | — | US | disclosed |
| WO-1994027987-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885HTR4 14/4885KCNH2 1156/4885 |
| US-20030139389-A1 | 5-HT4 receptor antagonists | HTR4, HTR6, HTR2C | HTR3A 35/4885HTR4 1/4885KCNH2 247/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885HTR4 14/4885KCNH2 1156/4885 |
| US-20020019386-A1 | 5-HT4 receptor antagonists | HTR4, HTR6, HTR2C | HTR3A 31/4885HTR4 1/4885KCNH2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.